

SAFE & QUALITY USE OF MEDICINES GROUP Meeting

Thursday 21st June 2007 Time: 9.30am to 3.30pm

Attendees

Beth Loe (Project Manager)
Avril Lee (WDHB)
Adam McRae (PHARMAC)
Peter Moodie (PHARMAC)
Marilyn Crawley (WDHB)

Debi Lawry (Otago)
Nigel Miller (Canterbury)
Mary Seddon (CMDHB)
Tim Maling (C&CDHB)
Gigi Lim (Auck Univ)

Minutes

Item	Topic/agenda	Notes/comments	Action Required
		Gigi Lim was welcomed and introduced to the group	
1.	Apologies	Gillian Bohm, Frances McClure, Elizabeth Plant, Kevin Hague	
2.	Minutes of previous meeting	<ul style="list-style-type: none"> Agreed 	
3.	Matters arising	<p>i. <u>Group membership</u></p> <ul style="list-style-type: none"> Gigi Lim (lecturer at the School of Nursing, Auckland University) has joined the group, the second DHB/GP applicant has not responded yet There has been no response from ACC about their consumers to date Medsafe still to be approached following discussion at the last meeting Debi's role has changed and she is moving to be nurse manager at Dunstan Hospital, keen to remain on the group and the rural trust is willing to fund her attendance at the meetings but not travel expenses <p>ii. <u>Inequitable funding issues</u></p> <ul style="list-style-type: none"> Letter sent to DG Health, cc Minister, replies awaited No feedback from CEO group available <p>iii. <u>International classification of drug interactions</u></p> <ul style="list-style-type: none"> postpone to next meeting <p>iv. <u>PreMec funding</u></p> <ul style="list-style-type: none"> No progress with this but it is urgent <p>v. <u>Linking ADR/allergy to NHI</u></p> <ul style="list-style-type: none"> Agenda Taranaki work for next meeting NZ Pharmacovigilance Centre invited to meeting, unable to attend but will attend August meeting, to discuss this and a possible national incident register <p>vi. <u>E pharmacy stock take</u></p> <ul style="list-style-type: none"> No updates available <p>vii. <u>Look alike sound alike names and packaging</u></p> <ul style="list-style-type: none"> Feedback on eyesight/lighting (literature search 	<p>i. <u>Group Membership</u></p> <ul style="list-style-type: none"> Follow up with ACC & then HDC about their consumers (Beth) Agreed to recommend that Debi continue on the group but that funding for her travel expenses needs to be available (Kevin) Letter to trust thanking them for sponsoring Debi to continue her membership (Beth) <p>ii. <u>Inequitable funding issues</u></p> <ul style="list-style-type: none"> Agenda at next meeting (Beth) <p>iii. <u>Drug interactions</u></p> <ul style="list-style-type: none"> Agenda (Beth) <p>iv. <u>PreMec funding</u></p> <ul style="list-style-type: none"> Re-write proposal to take to PreMec (Beth, Kevin) <p>v. <u>Linking ADR/allergy to NHI</u></p> <ul style="list-style-type: none"> Agenda for next meeting (Beth) <p>vi. <u>Pharmacy stock take</u></p> <ul style="list-style-type: none"> Agenda for next meeting (Beth) <p>vii. <u>Look alike sound alike names</u></p>

		underway)and any other progress at next meeting	Agenda (Beth)
4.	Terms of reference	<ul style="list-style-type: none"> The draft terms of reference were discussed It was agreed that the maximum no. of members would be 14 + the chair Changes were made to the membership representation, there was discussion about BPAC having representation on the group and this was a possibility but the current membership exceeds the agreed maximum A quorum of 8 was agreed Term of office agreed as 6 years with opportunity for re-appointment There was discussion around a conflict of interest clause Attendance fees, to be discussed with the chair 	<ul style="list-style-type: none"> Update draft and circulate for comment (Beth) Review point 9.1 (Kevin)
5.	Medicines Reconciliation	<ul style="list-style-type: none"> 5 responses to the questionnaire to date, one positive and one at planning stage High on QIC's priority list, some of the money allocated to bedside verification project can be invested in medicines reconciliation work Need to make a formal case to QIC Gather feedback from projects already undertaken nationally, produce a summary report, use expert knowledge as basis for project plan Formulate a project plan with costs & present to QIC by 3.8.07 Project based on production of a toolkit to include definition, examples of how, documentation etc, contacts, training standards, cost savings/benefits and evaluation 	<ul style="list-style-type: none"> Remind people about questionnaire (Avril) Put together project plan (Mary, Beth, Avril) Present project plan to QIC (Mary)
	SQM/QIC relationship	<ul style="list-style-type: none"> QIC has 8 key initiative areas What should the relationship between QIC/SQM be? Agenda QIC report for every meeting 	<ul style="list-style-type: none"> Explore relationship between QIC/SQM (Mary) Agenda QIC report at meetings (Beth)
6.	May conference debrief	<ul style="list-style-type: none"> Karen Jacobs & Matthew Broughton's (Pharmac) contribution to the conference should be acknowledged The table arrangement worked well The workshop reached some new people What didn't work: it was seen as a Pharmac conference not a joint one, the social marketing aspect didn't encourage attendance, timing not good because of clash with Operation Cruickshank, very few attendees from primary care, more workshop sessions would have been useful To reach primary care need to have a targeted content, different format and possibly repeat in 4 main centres 	<ul style="list-style-type: none"> Acknowledge contribution (Beth, Kevin)
7.	BPAC articles	<ul style="list-style-type: none"> Peter Black's article on antihypertensives will be used in the next edition The next edition is on drug interactions, heart failure and gout Do warning about colchicine 	<ul style="list-style-type: none"> Draft article (Mary, Beth)
8.	National Drug Chart Project	<ul style="list-style-type: none"> Question about why the Australian/UK chart were not adapted for use here There are criticisms of the Australian chart from users and some of the concepts have been included in the latest design 	<ul style="list-style-type: none"> Update project plan and distribute to members for final comment (Beth) Send project plan to QIC with covering letter from chair

		<ul style="list-style-type: none"> • Can the new version be easily changed for electronic prescribing • Additions to project plan: design of complex prescription charts and evaluation • Minor other changes • Plan needs to be sent to QIC 	(Beth, Kevin)
9.	High Risk Medicines		
9.i	Potassium & heparin pre mixes	<ul style="list-style-type: none"> • Potassium: avenues already explored to have these registered haven't worked. • Suggest write to chair of MARC, only other suggestion was to use pre-mixes as Section 29 or 25 product but neither are viable option in this case • Heparin: 7 DHBs have responded about strength of heparin pre mixes they would use, very little commonality and one DHB changing to only using syringes • Change to syringes result of an incident where 2 infusions accidentally both run at same rate so large amount of heparin infused in short time, all small volume infusions now given in syringes to avoid confusion with large volumes and rate 	<ul style="list-style-type: none"> • Write to chair of MARC re potassium pre mixes (Beth) • Complete log of strengths used (Beth) • Investigate if heparin syringes could be available commercially (Beth)
9.ii	Warfarin	<ul style="list-style-type: none"> • Have a nursing checklist for secondary care but have not been able to obtain a checklist for primary care although believe this is available • Work in progress 	<ul style="list-style-type: none"> • Checklist for primary care nurses (Avril, Mary) • Quotes for toolkit (Beth, Avril)
9.iii	Diltiazem	<ul style="list-style-type: none"> • Independent evaluation of penetration and impact of diltiazem alert 	<ul style="list-style-type: none"> • To bring proposal to next meeting (Adam)
9.iv	Heparin, LMWH	<ul style="list-style-type: none"> • Work on joint protocol for Auckland region needs to start • LMWH draft alert; standardise on renal impairment, both failure & impairment currently used, other feedback to be incorporated 	<ul style="list-style-type: none"> • Send updated LMWH alert to Peter (Beth)
9.v	Morphine	<ul style="list-style-type: none"> • Updates to draft alert agreed 	<ul style="list-style-type: none"> • Update draft alert (Marilyn, Beth)
9.vi	Intravenous Infusions	<ul style="list-style-type: none"> • Quality and Risk Managers have agreed to carry out the audit, all ready to go • Feedback to consultation has been analysed and updates to both alert and position statement agreed • Updated version will be available at the next meeting 	<ul style="list-style-type: none"> • Audit (Gillian, Beth) • Update alert/position statement (Marilyn, Beth)
9.vii	Good Prescribing Practice	<ul style="list-style-type: none"> • Distributed to agreed circulation list • Identified that there have been problems with scanned copies being sent to prescribers in secondary care, these are illegible • In future add a statement that the alert is available on the website or electronically from national coordinator 	<ul style="list-style-type: none"> • Update further alerts with statement about availability electronically (Beth)
9.viii	IT cytotoxic injection	<ul style="list-style-type: none"> • Issues identified with the website so the guidelines have not been loaded on yet. • Website format to be changed, this will make it more visible when a search engine is used and also make uploading material less complicated • Haematologist unable to help • Suggested take presentation to haematology meeting, to include NPSA video • One possibility is to apply for funding from external source eg Genesis Oncology Trust 	<ul style="list-style-type: none"> • Upload guidelines on to website when site updated (Beth) • Investigate taking guidelines and presenting to haematologists (Beth)

9.ix	Colchicine	<ul style="list-style-type: none"> Alert needs to be directed to primary care and community pharmacy Alert to include the alternative first line treatments To work on application to PTAC to restrict the number of tablets to 12 unless there is a justifiable reason for long term use 	<ul style="list-style-type: none"> Re-draft alert (Beth) Application to PTAC to restrict number of tablets per prescription (Mary, Adam, Peter M)
9.x	Oral Methotrexate	<ul style="list-style-type: none"> Awaiting response from John O'Donnell 	<ul style="list-style-type: none"> Contact John O'Donnell (Beth)
10.	Renal drug dosing	<ul style="list-style-type: none"> Agreed audience is all nursing and medical staff Alert still needs some re-wording to make message clear 	<ul style="list-style-type: none"> Re-format alert (Nigel)
11.	Community/hospital formulary, advice for SIG group	<ul style="list-style-type: none"> Supportive of concept of unified formulary Account needs to be taken of work already undertaken by other DHBs Need clarification of what is envisaged before we can provide expert advice around expenditure 	<ul style="list-style-type: none"> Reply to DHBNZ SIG (Beth)
12.	ACC research proposals	<ul style="list-style-type: none"> Postpone to next meeting 	<ul style="list-style-type: none"> Agenda item (Beth)
13.	Epipen availability and funding	<ul style="list-style-type: none"> As a group we are unable to do anything Best advice about the allocation of resource/funding would be PTAC Paper in NZMJ re use in hospital and suggesting that Epipens should be kept on the resus trolleys in place of adrenaline ampoules Not always appropriate to have Epipen on resus trolleys because staff struggle to use them in an emergency because of unfamiliarity Should we add adrenaline to our list of high risk drugs Not to be added to list of high risk medicines 	<ul style="list-style-type: none"> Reply to original question (Beth)
14.	Request by WDHB for Pharmac funding	<ul style="list-style-type: none"> Funding requested for heart failure, starting insulin etc booklets that have been developed by QUM pharmacists Agreed, inappropriate to fund for one DHB 	
15.	October meeting	<ul style="list-style-type: none"> Overlaps with Innovation awards and QIC meeting, suggest having a networking meeting 	<ul style="list-style-type: none"> Agenda at next meeting (Beth)
16.	Date of next meeting	<ul style="list-style-type: none"> August 9th in Auckland 	